Ibrutinib

Grey

Brand Name(s):Imbruvica

Indication:Chronic lymphocytic leukaemia (CLL)

Rationale:2

Considered:Nov-14

Review Date:Jul-22

Comments:
Drug Safety Update
Reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
Aug 17
…………………………
NICE TA452
NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from Janssen–Cilag
Jul-17
…………………………
NICE TA429
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Jan-17